AVE Science & Technology Co Ltd
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment China, Europe, the United States, Asia, Africa, and internationally. The company offers urine formed elements analyzer and related reagents, automatic urine ana… Read more
AVE Science & Technology Co Ltd (688067) - Net Assets
Latest net assets as of September 2025: CN¥518.37 Million CNY
Based on the latest financial reports, AVE Science & Technology Co Ltd (688067) has net assets worth CN¥518.37 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥611.46 Million) and total liabilities (CN¥93.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥518.37 Million |
| % of Total Assets | 84.78% |
| Annual Growth Rate | 13.98% |
| 5-Year Change | 109.47% |
| 10-Year Change | 236.09% |
| Growth Volatility | 26.93 |
AVE Science & Technology Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how AVE Science & Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AVE Science & Technology Co Ltd (2012–2024)
The table below shows the annual net assets of AVE Science & Technology Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥495.85 Million | +1.22% |
| 2023-12-31 | CN¥489.84 Million | +3.10% |
| 2022-12-31 | CN¥475.12 Million | -0.52% |
| 2021-12-31 | CN¥477.58 Million | +101.75% |
| 2020-12-31 | CN¥236.72 Million | -6.25% |
| 2019-12-31 | CN¥252.51 Million | +16.22% |
| 2018-12-31 | CN¥217.27 Million | +14.39% |
| 2017-12-31 | CN¥189.95 Million | +6.81% |
| 2016-12-31 | CN¥177.84 Million | +20.54% |
| 2015-12-31 | CN¥147.53 Million | +6.69% |
| 2014-12-31 | CN¥138.28 Million | +14.14% |
| 2013-12-31 | CN¥121.15 Million | +17.50% |
| 2012-12-31 | CN¥103.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AVE Science & Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1860.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥174.10 Million | 35.11% |
| Common Stock | CN¥68.00 Million | 13.71% |
| Other Comprehensive Income | CN¥28.96 Million | 5.84% |
| Other Components | CN¥224.78 Million | 45.33% |
| Total Equity | CN¥495.85 Million | 100.00% |
AVE Science & Technology Co Ltd Competitors by Market Cap
The table below lists competitors of AVE Science & Technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Francaise de l'Energie
LSE:0RIL
|
$122.04 Million |
|
Raymond Limited
NSE:RAYMOND
|
$122.08 Million |
|
Silicius Real Estate SOCIMI S.A.
MC:YSIL
|
$122.08 Million |
|
Jacobio Pharmaceuticals Group Co. Ltd.
PINK:JBPHF
|
$122.14 Million |
|
Yunnan Yuntou Ecology and Environment Technology Co Ltd
SHE:002200
|
$121.99 Million |
|
CNNC International Limited
F:U7MA
|
$121.99 Million |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
$121.96 Million |
|
The Nisshin OilliO GroupLtd.
OTCGREY:NSOMF
|
$121.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AVE Science & Technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 489,844,831 to 495,845,241, a change of 6,000,410 (1.2%).
- Net income of 22,841,204 contributed positively to equity growth.
- Dividend payments of 6,800,000 reduced retained earnings.
- Share repurchases of 10,031,871 reduced equity.
- Other comprehensive income increased equity by 28,930,534.
- Other factors decreased equity by 28,939,457.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥22.84 Million | +4.61% |
| Dividends Paid | CN¥6.80 Million | -1.37% |
| Share Repurchases | CN¥10.03 Million | -2.02% |
| Other Comprehensive Income | CN¥28.93 Million | +5.83% |
| Other Changes | CN¥-28.94 Million | -5.84% |
| Total Change | CN¥- | 1.22% |
Book Value vs Market Value Analysis
This analysis compares AVE Science & Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.94x to 3.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥2.06 | CN¥28.66 | x |
| 2013-12-31 | CN¥2.37 | CN¥28.66 | x |
| 2014-12-31 | CN¥2.74 | CN¥28.66 | x |
| 2015-12-31 | CN¥2.88 | CN¥28.66 | x |
| 2016-12-31 | CN¥3.49 | CN¥28.66 | x |
| 2017-12-31 | CN¥3.72 | CN¥28.66 | x |
| 2018-12-31 | CN¥4.22 | CN¥28.66 | x |
| 2019-12-31 | CN¥5.16 | CN¥28.66 | x |
| 2020-12-31 | CN¥4.68 | CN¥28.66 | x |
| 2021-12-31 | CN¥7.02 | CN¥28.66 | x |
| 2022-12-31 | CN¥6.99 | CN¥28.66 | x |
| 2023-12-31 | CN¥7.28 | CN¥28.66 | x |
| 2024-12-31 | CN¥7.38 | CN¥28.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AVE Science & Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.23%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.13x
- Recent ROE (4.61%) is below the historical average (12.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 18.97% | 28.60% | 0.56x | 1.18x | CN¥9.25 Million |
| 2013 | 16.75% | 24.77% | 0.58x | 1.17x | CN¥8.18 Million |
| 2014 | 12.39% | 21.51% | 0.49x | 1.16x | CN¥3.30 Million |
| 2015 | 16.64% | 26.54% | 0.56x | 1.13x | CN¥9.80 Million |
| 2016 | 17.03% | 25.88% | 0.55x | 1.19x | CN¥12.51 Million |
| 2017 | 13.14% | 18.60% | 0.60x | 1.18x | CN¥5.97 Million |
| 2018 | 12.56% | 18.12% | 0.58x | 1.19x | CN¥5.56 Million |
| 2019 | 20.01% | 26.59% | 0.64x | 1.18x | CN¥25.27 Million |
| 2020 | 12.72% | 16.70% | 0.61x | 1.25x | CN¥6.43 Million |
| 2021 | 6.55% | 14.85% | 0.38x | 1.15x | CN¥-16.48 Million |
| 2022 | 3.78% | 9.13% | 0.36x | 1.16x | CN¥-29.54 Million |
| 2023 | 4.40% | 10.75% | 0.36x | 1.14x | CN¥-27.45 Million |
| 2024 | 4.61% | 11.23% | 0.36x | 1.13x | CN¥-26.74 Million |
Industry Comparison
This section compares AVE Science & Technology Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,246,530,775
- Average return on equity (ROE) among peers: 12.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AVE Science & Technology Co Ltd (688067) | CN¥518.37 Million | 18.97% | 0.18x | $121.99 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |